Animal Models as Surrogates, SBIR Phase I ^ RFP No. PHS 2010-1 Topic #13

这份合同的目的是确定由于功能丧失突变而产生的有益表型，以确定在传统药物开发计划和治疗疾病中可以作为抑制目标的蛋白质。Kineta将使用另一种战略，利用现有的模式生物和遗传资源来识别药物替代突变(定义为赋予有益、类药物或健康表型的突变)。DS突变及其相关基因和基因产物是理想功能药物的蓝图。Kineta公司将开发一种药物代理本体论，它将被整合到现有的NCRR支持的资源中，以提供工具并明确支持药物发现。

The purpose of this contract is to identify beneficial phenotypes that are produced as a result of loss-of-function mutations to pinpoint proteins that can be targeted for inhibition in traditional drug development programs and treatment diseases. Kineta will use an alternative strategy that uses existing model organisms and genetic resources to identify Drug Surrogate Mutations (defined as mutations that confer beneficial, drug-like or health phenotypes). DS mutations and their associated genes and gene products serve as the blueprint for ideally functional drugs. Kineta, Inc. will develop a drug surrogate Ontology that will be integrated into existing NCRR-supported resources to provide tools and explicitly support drug discovery.